FGFR2 and cholangiocarcinoma: This phase II trial was a bridging study to assess whether the efficacy and safety findings for pemigatinib in FIGHT‐202 could be extrapolated to previously treated Chinese patients with cholangiocarcinoma carrying FGFR2 fusions or rearrangements.